The DEA hearing on whether to move marijuana more broadly from Schedule I to Schedule III began June 29, 2026, at the DEA Hearing Facility in Arlington, Virginia, and wrapped up July 15 to 16 following testimony from a handful of states opposing the change.

DEA Chief Administrative Law Judge Derek Julius closed the in-person proceedings without time allotted for closing arguments, so he set August 17, 2026 as the deadline for participants to file post-hearing briefs of up to 50 pages. He will use those briefs to write his own recommendation, but the final scheduling decision rests with the DEA Administrator on a timeline that has not been announced.

The DEA Administrator designated only parties opposed to rescheduling as official hearing participants, including Smart Approaches to Marijuana, the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, DUID Victim Voices, and the states of Nebraska, Idaho, Indiana, and Louisiana, on the grounds that supporters did not meet the legal definition of parties adversely affected by the proposed rule.

DEA and FDA officials defending the proposal still presented testimony highlighting marijuana’s medical benefits and its relative safety compared with alcohol and opioids, including from an FDA scientist and a New Hampshire physician, but reform advocacy groups were not seated as designated participants and criticized the hearing for not being livestreamed.

It is easy to conflate this hearing with rescheduling itself, but part of the reclassification already happened. In April 2026, the Acting Attorney General issued an order immediately moving state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III of the Controlled Substances Act.

The hearing that just concluded concerns a separate, broader rule that would move marijuana more comprehensively to Schedule III. That distinction matters clinically, because the interim reclassification is already producing downstream effects while the broader rule remains undecided.

Writing in Clinical Therapeutics on July 28, 2026, Johnson, Ledbetter, and Sherer argue that federal rescheduling lowers barriers to cannabis research but does not, by itself, generate the evidence clinicians need. They contend that states with mature medical cannabis markets and existing scientific and healthcare infrastructure are best positioned to lead the next phase of medical cannabis science.

Their specific proposal is state-authorized but independent research centers, supported by enabling legislation, sustained funding, and cross-sector partnerships, tasked with centralizing data infrastructure, standardizing metrics and documentation, and embedding equity-focused cannabis research into routine healthcare rather than treating it as a separate track.

The April interim reclassification is already reshaping federal paperwork and guidance in ways that touch clinical practice. The ATF has drafted an updated gun-purchase form that no longer flags medical marijuana use for recreational-only prohibition language, and the Treasury Department and IRS have said new tax guidance is coming for state-licensed cannabis businesses, which stand to gain federal deductions currently barred under IRC Section 280E.

Other agencies have held the line. The Department of Transportation has said state-legal medical cannabis is still no excuse for a positive drug test among truckers, pilots, and other safety-sensitive workers, and the Department of War issued a memo confirming marijuana use remains prohibited for service members and civilian employees, even under the interim rescheduling.

The hearing wrapping up is not the same as a decision being made. Judge Julius did not lay out an expected timeline for his recommendation or for the Administrator’s eventual action, and the broader rescheduling proposal is being challenged by several consolidated lawsuits from state attorneys general, rescheduling opponents, and at least one cannabis-focused biopharmaceutical company.

A congressional committee has also voted to block federal officials from taking further steps on rescheduling, though bipartisan lawmakers have told reporters they do not expect that provision to become law. None of this changes what the commentary is arguing, but it is the honest backdrop against which its call for state-led research infrastructure should be read.

This commentary lands at a specific, narrow moment: a formal hearing has closed, briefs are being prepared, and a recommendation has not yet been written, let alone acted on by the DEA Administrator. That is a meaningfully different moment than either the original April 2026 interim reclassification or a hypothetical future point where the broader rule is finalized.

The proposal for state-led, independent research infrastructure is not new to cannabis policy discussions, but it carries more weight now that federal rescheduling has already started changing what research is permissible. Whether states act on that opening, and whether independent research centers get built with real funding rather than remaining a proposal, will likely matter more to the evidence clinicians can rely on than the scheduling outcome alone.

What strikes me most about this moment is how easy it is to mistake a hearing ending for a decision being made. The hearing closing in mid-July is a procedural milestone, not a resolution, and the commentary’s authors are right to focus attention on what happens next rather than treating rescheduling itself as the finish line.

I agree with the paper’s central argument, but I would go further: research infrastructure without a clear plan for equitable patient access does not close the evidence gap that matters most in my exam room. States that want to lead this next phase need to fund real, independent research centers, not just announce intentions, and they need to build access alongside the science so that patients benefit from what gets learned.

Four questions worth asking before treating this as settled news